Inclusion Criteria:

- Histologically documented mesenchymal or mixed epithelial-mesenchymal tumor of the
ovary or uterus

- Patients with a primary diagnosis of FIGO I-IV uterine carcinosarcoma and optimum
debulking (postoperative residual tumor < 1cm) may be enrolled only if
cisplatin-ifosfamide combination therapy is not feasible.

- Patients with metastatic uterine carcinosarcoma may be enrolled only if
Ifosfamide/Paclitaxel combination therapy is not feasible.

- Patients with metastatic leiomyosarcoma may be enrolled only if gemcitabine-docetaxel
combination therapy is not feasible.

- Measurable (target lesion) tumor, evaluable (non-target lesion) tumor or histological
documentation

- No more than one prior chemotherapy. Any prior platinum or anthracycline- containing
chemotherapy must have been completed more than 6 months previously

- Prior radiotherapy ≤ 25% of the hematopoietic system is allowed provided it took
place more than 6 weeks before recruitment

- Patients are allowed to have received prior anticancer hormone therapy or specific
immunotherapy. Patients must have completed these therapies at least three weeks
before recruitment to the study

- All women with a theoretical possibility of pregnancy must produce a negative
pregnancy test (serum or urinary) within seven days before starting treatment

- General health of 0 - 2 on the ECOG score

- At least 18 years of age

- Estimated life expectancy above 12 weeks

- At least 3 weeks since major surgery

- Appropriate hematologic, renal and hepatic function in accordance with the following
definitions:

- Absolute neutrophil count (ANC) ≥ 1.5 × 109 /l

- Platelets ≥ 100 × 10 9/l

- Total bilirubin ≤ 1.25 times upper limit of normal

- Estimated GFR ≥ 50 ml/min

- LVEF > 50 %

- Informed consent must be obtained from all patients.

Exclusion Criteria:

- More than one prior chemotherapy (or radiochemotherapy)

- Active infection or other serious medical impairment liable to affect the patient's
ability to receive treatment according to protocol.

- Administration of other chemotherapy drugs or other anticancer hormone treatments
during the study.

- History of clinically manifest atrial or ventricular arrhythmia (> LOWN II) and
congestive heart failure, even if controlled by drugs (NYHA class > II). Documented
myocardial infarction within 6 months before study enrollment.

- Pregnant or breastfeeding women, or women not practicing appropriate birth control
methods

- Participation in another study using experimental drugs within the last 30 days

- Any other conditions or therapies which the physician believes might put the patient
at risk or impair the study objective.

- Known hypersensitivity to carboplatin or pegylated liposomal doxorubicin